// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

18,990
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
ALL STORIES · 18,990 results Live
FDA HIKMA Jul 15 — 0.00

FDA Approves Unknown Drug — HIKMA

HIKMA Pharmaceuticals announced the FDA approval of its Generic ANDA application, a strategic milestone expected to bolster market share and expand revenue within the competitive U…

FDA HIKMA Jul 12 — 0.00

FDA Approves Unknown Drug — HIKMA

HIKMA announced early FDA approval for its generic version of this pharmaceutical product on July 12, 2013, positioning itself to compete in this specific therapeutic market segmen…

FDA PH Jul 11 — 0.00

FDA Approves Unknown Drug — PH HEALTH

PH HEALTH has secured FDA approval for the pending generic application ANDA090733, a move that positions the company to capture new market share and diversify its revenue streams u…

FDA ACTAVIS Jul 11 — 0.00

FDA Approves Unknown Drug — ACTAVIS ELIZABETH

Actavis Elizabeth’s FDA approval of this ANDA clears the regulatory path for a generic entry, positioning the company to compete aggressively against the brand product and erode it…

FDA PH Jul 11 — 0.00

FDA Approves Unknown Drug — PH HEALTH

On July 11, 2013, PH HEALTH received FDA approval for ANDA090734, introducing a new therapeutic option to the market. This clearance is expected to generate significant revenue gro…

FDA Sun Jul 1 — 0.00

FDA Approves FINASTERIDE — Sun Pharmaceutical Industries, Inc.

# FDA Approves Sun Pharmaceutical's Generic Finasteride Sun Pharmaceutical Industries, Inc. received FDA approval for its generic finasteride formulation on July 1, 2013, marking …

FDA Novartis May 29 — 0.00

FDA Approves TAFINLAR — Novartis Pharmaceuticals Corporation

# FDA Approves Novartis's TAFINLAR (Dabrafenib) for Melanoma Treatment Novartis Pharmaceuticals Corporation received FDA approval for TAFINLAR (dabrafenib mesylate), an oral targe…

FDA Aurolife Apr 15 — 0.00

FDA Approves ACETAMINOPHEN AND CODEINE PHOSPHATE — Aurolife Pharma, LLC

On April 15, 2013, Aurolife Pharma, LLC received FDA approval for the ANDA representing acetaminophen and codeine phosphate tablets. This authorization strengthens the market offer…

FDA Janssen Mar 29 — 0.00

FDA Approves INVOKANA — Janssen Pharmaceuticals, Inc.

Janssen Pharmaceuticals received FDA approval for INVOKANA, a novel SGLT2 inhibitor for the treatment of type 2 diabetes, which is poised to capture significant market share and dr…

FDA Cranbury Mar 29 — 0.00

FDA Approves TRAMADOL HYDROCHLORIDE — Cranbury Pharmaceuticals, LLC

Cranbury Pharmaceuticals, LLC received FDA approval for its ANDA covering Tramadol Hydrochloride tablets, granting the company authorization to market the generic version of this p…

FDA Teva Mar 25 — 0.00

FDA Approves OLANZAPINE AND FLUOXETINE — Teva Pharmaceuticals USA, Inc.

# FDA Approves Generic Olanzapine and Fluoxetine Combination Teva Pharmaceuticals USA, Inc. received FDA approval for a generic version of the olanzapine and fluoxetine combinatio…

FDA BluePoint Mar 25 — 0.00

FDA Approves ZENATANE — BluePoint Laboratories

# FDA Approves BluePoint Laboratories' Generic Isotretinoin (Zenatane) BluePoint Laboratories received FDA approval for Zenatane (isotretinoin) oral formulation under ANDA 202099,…

FDA SUN Feb 22 — 0.00

FDA Approves Unknown Drug — SUN PHARM INDS LTD

# FDA Approves Generic Drug Application for Sun Pharmaceutical Sun Pharmaceutical Industries Ltd. received FDA approval for ANDA091037 on February 22, 2013, expanding its generic …

FDA Genentech, Feb 22 — 0.00

FDA Approves KADCYLA — Genentech, Inc.

Genentech announced today that the FDA has approved KADCYLA, an antibody-drug conjugate for HER2-positive breast cancer, signaling a strategic expansion in the oncology portfolio t…

FDA Celgene Feb 8 — 0.00

FDA Approves POMALYST — Celgene Corporation

# FDA Approves Celgene's POMALYST (pomalidomide) for Multiple Myeloma Treatment Celgene Corporation received FDA approval for POMALYST (pomalidomide), an oral immunomodulatory age…

FDA Chartwell Feb 5 — 0.00

FDA Approves CALCIUM ACETATE — Chartwell RX LLC

Chartwell RX LLC announced FDA approval for its generic Calcium Acetate oral tablets, positioning the company to enter the competing marketplace for phosphate binders used in chron…

FDA Actavis Jan 16 — 0.00

FDA Approves MORPHINE SULFATE — Actavis Pharma, Inc.

Actavis Pharma, Inc. has received FDA approval for its Abbreviated New Drug Application (ANDA) for morphine sulfate oral solid dosage forms, potentially broadening access to this c…

FDA Micro Dec 14 — 0.00

FDA Approves TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN — Micro Labs Limited

Micro Labs Limited secured FDA approval for its Tramadol Hydrochloride and Acetaminophen oral tablet formulation, expanding its product portfolio in the U.S. pain management market…

FDA Pfizer Nov 6 — 0.00

FDA Approves XELJANZ — Pfizer Laboratories Div Pfizer Inc

FDA approved XELJANZ (tofacitinib citrate) from Pfizer Laboratories, a new oral treatment for rheumatoid arthritis, paving the way for the company to capture a significant share of…

FDA Par Nov 2 — 0.00

FDA Approves OLANZAPINE AND FLUOXETINE — Par Health USA, LLC

# FDA Approves Par Pharmaceutical's Generic Olanzapine and Fluoxetine Combination Par Pharmaceutical's approval of generic olanzapine and fluoxetine (ANDA077742) on November 2, 20…